RxDoctor Payments Data

Michael Sims, PA

Physician Assistant · Longview, TXNPI 1427053180

Payments from drug & device makers

$8,845in general payments, 2019–2025

Across 578 payments — averaging $15.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • GSK$949
  • AbbVie$890
  • Pfizer$791
  • Lilly USA, LLC$608
  • AstraZeneca$586
  • plus $4K from 44 others

What the payments were for

  • Food & beverage$8,845100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,845 in reported general payments places this provider in the 95th percentile of 8,308 physician assistant providers in Texas.

See all physician assistant providers in Texas

Medicare billing

Part B allowed, 2024
$174,123
Medicare patients
295
Services billed
7,619

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide41$65,395
MounjaroTirzepatide38$58,760
FarxigaDapagliflozin Propanediol42$47,590
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$27,628
JardianceEmpagliflozin31$27,400
JanuviaSitagliptin Phosphate14$20,804
TrulicityDulaglutide19$18,542
Repatha SureclickEvolocumab21$15,289
XareltoRivaroxaban14$13,745
EliquisApixaban11$13,211
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr14$6,175
MovantikNaloxegol Oxalate11$4,285
Albuterol Sulfate HfaAlbuterol Sulfate60$2,360
Atorvastatin Calcium257$2,161
Gabapentin119$1,839

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$608$77,30357 claims
Novo NordiskOzempic$1,080$65,39541 claims
AstraZenecaFarxiga$586$47,59042 claims
GSKTrelegy Ellipta, Anoro Ellipta$949$33,80338 claims
Boehringer IngelheimJardiance$468$27,40031 claims
MerckJanuvia$384$20,80414 claims
Johnson & JohnsonXarelto$106$13,74514 claims
PfizerEliquis$791$13,21111 claims
Almatica Pharma LLCSertraline Hcl$18$1,10995 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,308 physician assistant providers in Texas.

Other physician assistant in Longview

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →